Tumor-Derived Extracellular Vesicles: Modulation of Cellular Functional Dynamics in Tumor Microenvironment and Its Clinical Implications.
cell communication
extracellular vesicles
functional dynamics
tumor microenvironment
tumor progression
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
07
2021
accepted:
09
08
2021
entrez:
17
9
2021
pubmed:
18
9
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Cancer can be described as a dynamic disease formed by malignant and stromal cells. The cellular interaction between these components in the tumor microenvironment (TME) dictates the development of the disease and can be mediated by extracellular vesicles secreted by tumor cells (TEVs). In this review, we summarize emerging findings about how TEVs modify important aspects of the disease like continuous tumor growth, induction of angiogenesis and metastasis establishment. We also discuss how these nanostructures can educate the immune infiltrating cells to generate an immunosuppressive environment that favors tumor progression. Furthermore, we offer our perspective on the path TEVs interfere in cancer treatment response and promote tumor recurrence, highlighting the need to understand the underlying mechanisms controlling TEVs secretion and cargo sorting. In addition, we discuss the clinical potential of TEVs as markers of cell state transitions including the acquisition of a treatment-resistant phenotype, and their potential as therapeutic targets for interventions such as the use of extracellular vesicle (EV) inhibitors to block their pro-tumoral activities. Some of the technical challenges for TEVs research and clinical use are also presented.
Identifiants
pubmed: 34532325
doi: 10.3389/fcell.2021.737449
pmc: PMC8438177
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
737449Informations de copyright
Copyright © 2021 Santos, Bustos, Bhatt, Chammas and Andrade.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncogene. 2020 Jan;39(2):428-442
pubmed: 31485019
Ann Intern Med. 1975 Jan;82(1):96-100
pubmed: 799908
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Hematol Oncol. 2020 Nov 19;13(1):156
pubmed: 33213490
Autophagy. 2020 Nov;16(11):2069-2083
pubmed: 31920150
Cell Mol Life Sci. 2016 Dec;73(24):4717-4737
pubmed: 27438886
Cell Death Dis. 2020 Jan 22;11(1):43
pubmed: 31969559
Nucleic Acids Res. 2019 Jan 8;47(D1):D516-D519
pubmed: 30395310
J Extracell Vesicles. 2019 Nov 15;8(1):1690217
pubmed: 31819794
Cell Death Dis. 2019 Nov 4;10(11):829
pubmed: 31685807
Semin Cell Dev Biol. 2018 Nov;83:36-41
pubmed: 29580970
Oncogene. 2018 Aug;37(31):4239-4259
pubmed: 29713056
ACS Nano. 2016 Mar 22;10(3):3323-33
pubmed: 26938862
Oncol Res. 2017 May 24;25(5):651-661
pubmed: 27712599
PLoS One. 2012;7(12):e50999
pubmed: 23251413
J Cell Physiol. 2019 Aug;234(10):16885-16903
pubmed: 30793767
EMBO J. 2017 Jul 3;36(13):1811-1836
pubmed: 28596378
Membranes (Basel). 2021 Mar 12;11(3):
pubmed: 33809102
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Exp Mol Med. 2019 Aug 9;51(8):1-13
pubmed: 31399559
Signal Transduct Target Ther. 2020 Aug 5;5(1):145
pubmed: 32759948
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
J Cell Mol Med. 2020 Jan;24(1):588-604
pubmed: 31724333
Int J Mol Sci. 2021 May 11;22(10):
pubmed: 34064646
Nat Rev Mol Cell Biol. 2020 Oct;21(10):585-606
pubmed: 32457507
Biochem Biophys Res Commun. 2017 Oct 21;492(3):356-361
pubmed: 28851650
Int J Nanomedicine. 2019 Oct 07;14:8121-8132
pubmed: 31632022
J Extracell Vesicles. 2019 Apr 11;8(1):1597614
pubmed: 31007876
Trends Cancer. 2020 Sep;6(9):767-774
pubmed: 32307267
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
JCI Insight. 2019 Dec 5;4(23):
pubmed: 31661464
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
J Immunother Cancer. 2018 Dec 10;6(1):145
pubmed: 30526680
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
Nat Commun. 2018 Dec 19;9(1):5395
pubmed: 30568162
Nat Commun. 2018 Jun 11;9(1):2270
pubmed: 29891938
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
J Cell Sci. 2018 Aug 3;131(15):
pubmed: 30076239
Int J Biol Sci. 2017 Sep 21;13(10):1287-1296
pubmed: 29104495
Clin Sci (Lond). 2020 Apr 17;134(7):807-825
pubmed: 32219336
Oncol Rep. 2016 Nov;36(5):2535-2543
pubmed: 27599779
Sci Rep. 2019 Oct 9;9(1):14482
pubmed: 31597943
Front Oncol. 2020 Jun 18;10:982
pubmed: 32626660
Nat Commun. 2020 Mar 5;11(1):1211
pubmed: 32139701
Neoplasia. 2018 Aug;20(8):775-788
pubmed: 29981499
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Mol Ther. 2019 Oct 2;27(10):1772-1783
pubmed: 31416776
PLoS One. 2012;7(10):e46737
pubmed: 23091600
Mol Oncol. 2021 Jan;15(1):3-26
pubmed: 33207034
J Exp Med. 2019 Dec 2;216(12):2883-2899
pubmed: 31548301
Nat Cell Biol. 2019 Feb;21(2):190-202
pubmed: 30598531
Nanomedicine. 2016 Apr;12(3):655-664
pubmed: 26586551
Sci Rep. 2016 Dec 12;6:38541
pubmed: 27941871
J Exp Clin Cancer Res. 2018 Oct 3;37(1):242
pubmed: 30285793
Clin Cancer Res. 2019 Jan 1;25(1):266-276
pubmed: 30287549
Dev Cell. 2021 Jul 12;56(13):1989-2006.e6
pubmed: 34118203
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5930-E5939
pubmed: 28684402
Sci Rep. 2018 Jun 12;8(1):8973
pubmed: 29895824
Oncogene. 2019 Jun;38(26):5158-5173
pubmed: 30872795
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Commun Biol. 2019 Oct 18;2:386
pubmed: 31646189
Nat Cell Biol. 2020 Feb;22(2):137-139
pubmed: 31992866
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330
pubmed: 32543905
J Extracell Vesicles. 2019 Aug 27;8(1):1656993
pubmed: 31497265
Nat Cell Biol. 2015 Feb;17(2):183-94
pubmed: 25621950
Neoplasia. 2017 Nov;19(11):932-940
pubmed: 28963969
Theranostics. 2019 Oct 18;9(26):8206-8220
pubmed: 31754391
Cancer Lett. 2018 Oct 28;435:80-91
pubmed: 30098399
Mol Carcinog. 2015 Jul;54(7):554-65
pubmed: 24347249
Oncogene. 2018 Jul;37(28):3806-3821
pubmed: 29636548
Cell Mol Life Sci. 2021 Mar;78(6):3057-3072
pubmed: 33237352
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
PLoS One. 2014 May 15;9(5):e97580
pubmed: 24831807
Sci Rep. 2020 Jan 9;10(1):92
pubmed: 31919420
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Sci Adv. 2018 Mar 07;4(3):eaar2766
pubmed: 29532035
J Extracell Vesicles. 2017 Aug 8;6(1):1359479
pubmed: 28815003
Biomed Pharmacother. 2021 Jan;133:111016
pubmed: 33246226
Matrix Biol. 2018 Jan;65:104-118
pubmed: 28888912
Biochim Biophys Acta Proteins Proteom. 2019 Dec;1867(12):140203
pubmed: 30822540
Cancers (Basel). 2016 Dec 09;8(12):
pubmed: 27941677
Nat Cell Biol. 2015 Mar;17(3):300-10
pubmed: 25686249
Cancer Biomark. 2018;22(2):267-274
pubmed: 29660899
Leukemia. 2009 Sep;23(9):1643-9
pubmed: 19369960
Oncotarget. 2018 Nov 16;9(90):36083-36101
pubmed: 30546829
Cell Death Differ. 2009 Jan;16(1):175-83
pubmed: 18846108
J Exp Clin Cancer Res. 2019 May 17;38(1):201
pubmed: 31101062
Mol Cancer. 2020 Mar 30;19(1):68
pubmed: 32228703
Semin Cancer Biol. 2020 Jun;63:11-18
pubmed: 31323289
Mol Ther. 2018 Oct 3;26(10):2466-2475
pubmed: 30120059
Nat Rev Mol Cell Biol. 2019 Sep;20(9):509-510
pubmed: 31324871
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
Oncol Lett. 2019 Oct;18(4):4082-4091
pubmed: 31516608